Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: A randomized study

European Journal of Endocrinology

Volumn 150, Issue 5, 2004, Pages 705-714

  Morin Papunen, L C ^b   Vauhkonen, I ^a   Ruokonen, A ^b   Tapanainen, Juha S ^b   Raudaskoski, T ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DYDROGESTERONE; ESTRADIOL VALERATE; ESTROFEM; GLUCOSE; INSULIN; TIBOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INSULIN CLEARANCE; INSULIN METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; BLOOD GLUCOSE; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LINEAR MODELS; LIPID METABOLISM; MIDDLE AGED; NORPREGNENES; OBESITY; OXIDATION-REDUCTION; POSTMENOPAUSE;

EID: 2942755651     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500705     Document Type: Article

References (52)

1. Proudler AJ, Felton CV & Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clinical Science 1992 83 489-494.
2. Walton C, Godsland IF, Proudler AJ, Wynn V & Stevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. European Journal of Clinical Investigation 1993 23 466-473.
3. Stout RW. Insulin and atheroma 20-yr perspective. Diabetes Care 1990 13 631-654.
4. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. New England Journal of Medicine 1993 328 1069-1075.
5. Bush TL. Extraskeletal effects of estrogen and the prevention of atherosclerosis. Osteoporosis International 1991 2 5-11.
6. Barrett-Connor E & Bush TL. Estrogen and coronary heart disease in women. Journal of the American Medicine Association 1991 265 1861-1867.
7. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speitzer FE et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. New England Journal of Medicine 1991 325 756-762.
8. Barrett-Connor E & Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990 10 531-534.
9. Barrett-Connor E & Stuenkel CA. Hormone replacement therapy (HRT) - risks and benefits. Internal Journal of Epidemiology 2001 30 423-426.
10. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. Journal of Internal Medicine 1996 738 (Suppl) 1-60.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321-333.
12. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association 1998 280 605-613.
13. Spellacy WN, Buhi WC & Birk SA. The effects of norgestrel on carbohydrate and lipid metabolism over one year. American Journal of Obstetrics and Gynecology 1976 125 984-986.
14. Elkind-Hirsch KE, Sherman LD & Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. Journal of Clinical Endocrinology and Metabolism 1993 76 472-475.
15. Godsland IF, Gangar K, Walton C, Cust MP, Whitehead MI, Wynn V et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993 42 846-853.
16. De Cleyn K, Buytaert P & Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas 1989 11 235-242.
17. Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. British Journal of Obstetrics and Gynaecology 1997 104 4-13.
18. van der Vies J. Pharmacological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Maturitas 1987 (Suppl 1) 15-24.
19. Crona N, Samsioe G, Lindberg UB & Silfverstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas 1988 9 303-308.
20. Rymer J, Chapman MG, Fogelman I & Wilson PO. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994 18 127-133.
21. Lindsay R, Hart DM & Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. British Medical Journal 1980 280 1207-1209.
22. Geusens P, Dequeker J, Gielen J & Schot LP. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991 13 155-162.
23. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM & Tax L. Org OD 14 and the endometrium. Maturitas 1991 13 243-251.
24. Tax L, Goorissen EM & Kicovic PM. Clinical profile of Org OD 14. Maturitas 1987 (Suppl) 3-13.
25. De Aloysio D, Fabiani AG, Mauloni M & Bottiglioni F. Use of Org OD 14 for the treatment of climacteric complaints. Maturitas 1987 (Suppl) 49-65.
26. Moore RA. Livial: a review of clinical studies. British Journal of Obstetrics and Gynaecology 1999 106 1-21.
27. Hanggi W, Lippuner K, Riesen W, Jaeger P & Birkhauser MH. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomized study. British Journal of Obstetrics and Gynaecology 1997 104 708-717.
28. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM & Melis GB. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1997 82 251-253.
29. Crona N, Silfverstolpe G & Samsioe G. A double-blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinologica 1983 102 451-455.
30. Prelevic GM, Beljic T, Balint-Peric L & Ginsburg J. Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus. Maturitas 1998 28 271-276.
31. Anonymous. Report of the expert committee on the diagnosis and classification of diabetes mellitus. (see comments) Diabetes Care 1997 20 1183-1197.
32. DeFronzo RA, Tobin JD & Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979 237 E214-E223.
33. Moghetti P, Tosi F, Castello R, Magnani CM, Nergri C, Brun E et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. Journal of Clinical Endocrinology and Metabolism 1996 81 952-960.
34. Laakso M, Uusitupa M, Takala J, Majander H, Reijonen T & Penttila I. Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects. Metabolism: Clinical and Experimental 1988 37 1092-1100.
35. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism: Clinical and Experimental 1988 37 287-301.
36. Shuster LT, Go VL, Rizza RA, O'Brien PC & Service FJ. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes 1988 37 200-203.
37. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treatcher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
38. Altman D. Practical Statistics for Medical Research, Serial Measurements, pp 426-430. Chapman & Hall: London, 1991.
39. Polderman KH, Gooren LJ, Asscheman H, Bakker A & Heine RJ. Induction of insulin resistance by androgens and estrogens. Journal of Clinical Endocrinology and Metabolism 1994 79 265-271.
40. Holmang A, Svedberg J, Jennische E & Bjorntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. American Journal of Physiology 1990 259 E555-E560.
41. Schalin-Jantti C, Laurila E, Lofman M & Groop LC. Determinants of insulin-stimulated skeletal muscle glycogen metabolism in man. European Journal of Clinical Investigation 1995 25 693-698.
42. Wiegratz I, Starflinger F, Tezloff W, Leifels-Fischer B, Helmond FA, Dericks-Tan JS et al. Effect of tibolone compared with sequentiel hormone replacement therapy on carbohydrtae metabolism in postmenopausal women. Maturitas 2002 41 133-141.
43. Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stanczyk FZ & Lobo RA. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertility and Sterility 1994 62 1176-1180.
44. Cucinelli F, Paparella P, Soranna L, Barini A, Cinque B, Mancuso S et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. European Journal of Endocrinology 1999 140 215-223.
45. Randle R, Hales C, Garlandy P & Newsholme E. The glucose fatty acid cycle and its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963 i 785-789.
46. Krakower GR, Meier DA & Kissebah AH. Female sex hormones, perinatal, and peripubertal androgenization on hepatocyte insulin dynamics in rats. American Journal of Physiology 1993 264 E342-E347.
47. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V & Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine 1991 325 1196-1204.
48. O'Sullivan AJ, Crampton LJ, Freund J & Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. Journal of Clinical Investigation 1998 102 1035-1040.
49. Deng HW, Li J, Li JL, Dowd R, Davies KM, Johnson M et al. Association of estrogen receptor-alpha genotypes with body mass index in normal healthy postmenopausal Caucasian women. Journal of Clinical Endocrinology and Metabolism 2000 85 2748-2751.
50. Stevenson JC, Proudler AJ, Walton C & Godsland IF. HRT mechanisms of action: carbohydrates. Internal Journal of Fertility and Menopausal Studies 1994 39 50-55.
51. Crook D, Godsland IF, Hull J & Stevenson JC. Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. British Journal of Obstetrics and Gynaecology 1997 104 298-304.
52. DeFronzo RA, Bonadonna RC & Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992 15 318-368.